Neurones (NE9) AI Stock Analysis

1 Followers

Neurones

(Frankfurt:NE9)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Steady Revenue and Profit GrowthSustained revenue expansion across 2020–2025, combined with solid EBIT margins and an improved net margin, indicates durable demand for Neurones’ consulting and IT services. This growth provides a broader base for recurring client work and supports continued investment in specialist capabilities.

Negative Factors

Gross-Margin VolatilityLarge gross-margin swings make it harder to assess the underlying durability of reported profitability. They may reflect changes in cost mix or classification and create uncertainty about how consistently revenue growth will translate into gross profit, even though EBIT and net margins remain positive.

Neurones (NE9) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 984.40M
Dividend Yield: 3.46%
Average Volume (3M): ―
Price to Earnings (P/E): 18.0
Beta (1Y): 0.42
Revenue Growth: 6.68%
EPS Growth: 9.16%
Country: Germany
Employees: 7,329
Sector: Technology
Sector Strength: 61
Industry: Information Technology Services

Neurones Business Overview & Revenue Model

Company Description

Neurones S.A., an information technology (IT) services provider founded in 1984 and headquartered in Nanterre, France, operates with a global reach. The company delivers a broad spectrum of services encompassing infrastructure, application developmen...

Neurones Peers Comparison

Overall Rating

UnderperformOutperform

Sector (61)

Financial Indicators

DE:NE9 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FR:WAVE	83Outperform	EUR 845.67M	10.60	12.19%	1.41%	1.13%	8.32%
FR:SOP	77Outperform	EUR 3.82B	12.75	14.45%	2.67%	1.62%	12.95%
FR:CAP	76Outperform	EUR 21.01B	15.53	11.82%	2.69%	6.23%	-11.48%
FR:ATE	66Neutral	EUR 3.05B	21.62	6.19%	1.71%	0.11%	-6.28%
Sector *	61Neutral	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%
FR:ATO	42Neutral	EUR 488.06M	-0.40	117.34%	―	-14.39%	-173.10%

* Technology Sector Average

Performance Comparison

DE:NE9 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:NE9	Neurones	40.50	-0.43	-1.06%
FR:ATE	ALTEN	87.55	20.93	31.42%
FR:ATO	Atos SE	24.04	-20.19	-45.64%
FR:CAP	Capgemini	126.55	-2.79	-2.16%
FR:SOP	Sopra Steria	198.40	72.15	57.15%
FR:WAVE	Wavestone SA	35.40	-13.90	-28.20%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Neurones AI Stock Analysis